iTeos: Developing IO Therapeutics For Hot And Cold Tumors
Emerging Company Profile: Not many young academic spin-outs can claim a clinical-stage collaboration with a big pharma, but iTeos Therapeutics ‒ a Belgian company developing novel cancer therapies ‒ can do just that.
You may also be interested in...
Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.
Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.
IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.